Brief: First Patient Dosed In Phase Ii Trial To Treat Complications In Covid-19
16/10/2020 12:16
Arch Biopartners Inc ARCH.V :
* FIRST PATIENT DOSED IN PHASE II TRIAL TO TREAT
COMPLICATIONS IN
COVID-19
* ARCH BIOPARTNERS INC - DOSED FIRST PATIENT IN PHASE II
TRIAL OF
ITS LEAD DRUG LSALT PEPTIDE
Source text for Eikon: ID:nGNXWqYtG
Further company coverage: ARCH.V
Recent news on Arch Biopartners
See all newsBrief: Arch Biopartners To Expand Phase Ii Cardiac Surgery-Associated Acute Kidney Injury Trial To The US
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Strengthens Its Position As A Leading Kidney Therapeutics Company With The Acquisition Of A Breakthrough Platform To Develop New Drugs Targeting Chronic Kidney Disease (Ckd)
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Biopartners Announces Ontario Research Ethics Board Approval To Start Phase II Trial For LSALT Peptide